BJG-05-039
BJG-05-039 is a PAK1-selective degrader consisting of NVS-PAK1-1 conjugated to Lenalidomide (HY-A0003). BJG-05-039 induces selective degradation of PAK1. BJG-05-039 inhibits phosphorylation of MEK S298, as well as inhibiting phosphorylation of ERK. BJG-05-039 has an anti-proliferative effect on PAK1-dependent cell lines[1].
Product Specifications
CAS Number
3009849-06-0
UNSPSC
12352005
Target
MEK; PAK; PERK
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway
Field of Research
Cancer
Smiles
FC(F)CN1C2=C(C=C(Cl)C=C2)C(N[C@H]3CCN(C(NCCCCCCCCNC4=CC=CC(C(N5C6CCC(NC6=O)=O)=O)=C4C5=O)=O)C3)=NC7=CC(F)=CC=C17
Molecular Formula
C41H44ClF3N8O5
Molecular Weight
821.29
References & Citations
[1]Chow HY, et al. Development and Utility of a PAK1-Selective Degrader. J Med Chem. 2022 Dec 8;65 (23) :15627-15641.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
gamma TubULin (TUBG1) Human Gene Knockout Kit (CRISPR)
LOC132707 Human qPCR Primer Pair (XM_067995)
